Theraclone Sciences's competitors

Theraclone Sciences's competitors include Keryx Biopharmaceuticals, Reneuron Group, Oxford Nanopore Technologies and Fate Therapeutics
Add company...
Theraclone Sciences
A privately-held biotechnology company focused on developing novel tumor- specific therapeutic antibodies for the treatment of cancer and infectious disease.
Keryx Biopharmaceuticals
Keryx Biopharmaceuticals is a biopharmaceutical company focused on the development of products for the treatment of renal diseases.
Reneuron Group
ReNeuron Group engages in R&D and the commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.
Oxford Nanopore Technologies
Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA and proteins.
Fate Therapeutics
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Founding Date
Founding Date
2004
Founding Date
1998
Founding Date
1997
Founding Date
2005
Founding Date
2007
Type
Type
Private
Type
Public
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
Seattle, US HQ
Locations
New York, US HQ
Boston, US
Locations
Surrey Research Park, GB HQ
Locations
Oxford, GB HQ
Locations
San Diego, US HQ
Employees
Employees
109% decrease
Employees
193
Employees
5320% increase
Employees
2972% increase
Employees
66
Valuation ($)
Valuation ($)
N/A
Valuation ($)
615.5 m
Valuation ($)
73.5 m
Valuation ($)
1.6 b
Valuation ($)
595.7 m
Twitter followers
Twitter followers
N/A
Twitter followers
391
Twitter followers
N/A
Twitter followers
22.7 k
Twitter followers
853

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$60.6m (FY, 2017)
Revenue (est.)
£46k (FY, 2017)
Revenue (est.)
£4.5m (FY, 2016)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$22m (FY, 2017)
Cost of goods
N/A
Cost of goods
£3.7m (FY, 2016)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$38.7m (FY, 2017)
Gross profit
N/A
Gross profit
£867k (FY, 2016)
Gross profit
N/A
Net income
Net income
N/A
Net income
($163.4m) (FY, 2017)
Net income
(£15.6m) (FY, 2017)
Net income
(£59.1m) (FY, 2016)
Net income
($43m) (FY, 2017)

Funding

Latest funding round
Latest funding round
$ 3.1m (about 3 years ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 139.9m (2 months ago)
Latest funding round
N/A
Total funding raised
Total funding raised
$ 58.2m
Total funding raised
N/A
Total funding raised
$ 38.4m
Total funding raised
$ 765m
Total funding raised
$ 200.4m
For sources of this data, please see the company profileDownload Excel

View company profiles

Keryx Biopharmaceuticals
HQ
New York, US
Employees
193

Keryx Biopharmaceuticals is a biopharmaceutical company focused on the development of products for the treatment of renal diseases.

View company
Reneuron Group
HQ
Surrey Research Park, GB
Employees
53↑ 20% increase

ReNeuron Group engages in R&D and the commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.

View company
Oxford Nanopore Technologies
HQ
Oxford, GB
Employees
297↑ 2% increase

Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA and proteins.

View company
Fate Therapeutics
HQ
San Diego, US
Employees
66

Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.

View company